All lobbying filings

THE MCMANUS GROUP

Lobbying for BIOWOUND SOLUTIONS · Biologics Company

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Nevada

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Medicine Access and Reform Act (H.R. 6852)

Bills named in this filing 3

H.R. 5768
Skin Substitute Access and Payment Reform Act
S. 2561
Skin Substitute Access and Payment Reform Act of 2025
H.R. 6852
Advanced Wound Care and Regenerative Medicine Access and Reform Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.